Infectious Diseases Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

Description

Persistence Market Research has recently published an in-depth report on the global infectious diseases diagnostics market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and diagnostics sectors.

Key Insights:

Global Market Revenue (2022): US$ 35.1 Billion
Estimated Market Value (2033): US$ 55.1 Billion
Global Market Growth Rate (CAGR 2022-2033): 4.2%

Global Infectious Diseases Diagnostics Market - Report Scope:

The infectious diseases diagnostics market includes the development, production, and distribution of diagnostic test kits and systems used to identify infectious diseases. The market covers a wide range of diseases, including respiratory infections, sexually transmitted infections (STIs), and other contagious diseases that require timely and accurate diagnosis for effective treatment.

Market Growth Drivers:

Rising Incidence of Infectious Diseases

The global prevalence of infectious diseases continues to rise, driving demand for effective diagnostic solutions. Respiratory diseases and sexually transmitted infections are particularly on the rise, necessitating increased diagnostic testing to manage and control these diseases. For instance, according to World Bank data, 37.7 million people were living with HIV in 2020, with women and girls comprising half of this population. The need for accurate diagnosis and timely treatment of such infections is expected to boost the demand for infectious diseases diagnostics.

Rising Focus on Evidence-Based Medicine (EBM)

Evidence-based medicine (EBM) is gaining importance in the healthcare environment as it helps clinicians achieve higher quality care, improved patient satisfaction, and lower costs. EBM not only involves using evidence to develop treatment protocols but also encourages dialogue between patients and clinicians, allowing patients to participate in decision-making. The emphasis on evidence-based diagnosis is driving the demand for diagnostic kits, as clinicians rely on accurate diagnostic results to guide treatment decisions.

Increasing Demand for Rapid Diagnostic Tests (RDTs)

The demand for rapid diagnostic tests (RDTs) is growing as more patients suffer from infectious diseases that require quick and accurate diagnosis. For example, the World Health Organization (WHO) reported that 3.1 billion RDTs for malaria were sold worldwide between 2010 and 2020, with 81% of these sales going to sub-Saharan African nations. The need for reliable, low-cost diagnostic kits is increasing, presenting significant opportunities for market growth.

Market Challenges:

High Cost of Diagnostic Test Kits

While the market for infectious diseases diagnostics is expanding, the high cost of available diagnostic test kits remains a significant challenge. There is a need for cost-effective test kits with high specificity and sensitivity to make diagnostics more accessible, particularly in low-resource settings. The high cost of current diagnostic tools limits their widespread adoption, especially in developing countries.

Lack of Efficient Diagnostic Test Kits

There is a scarcity of efficient diagnostic test kits for many infectious diseases. The development of affordable and reliable test kits is essential to meet the growing demand for diagnostics in both high-income and low-income regions. Companies are increasingly focusing on research and development to create highly accurate and sensitive diagnostic kits, which is expected to open up new business opportunities in the market.

Opportunities for Growth:

Focus on Infectious Disease Prevention

Different nations are concentrating on preventing infectious diseases to reduce healthcare expenditures. For example, the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is calling for innovations to address urgent issues affecting the control, treatment, and cure of infectious diseases. Such initiatives present strong growth opportunities for suppliers of diagnostic kits for infectious diseases, as governments and healthcare organizations seek to enhance their diagnostic capabilities.

Expansion of Research and Development Efforts

The expanding research and development efforts aimed at producing highly accurate and sensitive diagnostic kits are expected to create new business prospects for companies involved in infectious diseases diagnostics. The focus on innovation and the development of more effective diagnostic solutions will likely drive the market's growth in the coming years.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the global infectious diseases diagnostics market?
Which consumer segments are leading the adoption of infectious diseases diagnostic solutions?
How are technological advancements influencing the competitive landscape?
Who are the key players in the global infectious diseases diagnostics market, and what strategies are they employing to maintain their market position?
What are the emerging trends and future prospects in the global infectious diseases diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global infectious diseases diagnostics market, such as Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, are focusing on product innovation, strategic collaborations, and expanding their market presence in emerging economies. These companies are investing heavily in research and development to create advanced diagnostic kits that offer enhanced accuracy and affordability. Collaborations with healthcare providers and governments are enhancing market credibility and driving the adoption of new technologies.

Key Companies Profiled:

Affymetrix, Inc.
Ambion, Inc.
Applera Corporation
Cenetron Diagnostics
Cepheid, Inc.
Chiron Corporation
Dharmacon, Inc.
Digene Corporation
Gen-Probe Incorporated
Innogenetics NV
Nanogen, Inc.
F. Hoffmann-La Roche Ltd
Becton, Dickinson and Company
bioMerieux SA
Hologic, Inc.,
QIAGEN
Myriad Genetics, Inc.,
Thermo Fisher Scientific
Meridian Bioscience, Inc.

Key Segments Covered in Infectious Diseases Diagnostics Industry Research

Product:

Instrument
Kits and reagents
consumables

Test Type:

Screening Test
Diagnostic Test

Application:

Hospital- Acquired Infections
Sexually Transmitted Disease (STD)
Sepsis
Meningitis
Respiratory Infections
HPV
Gastrointestinal Tract Infections
Infection in Transplant Patients
Hepatitis B and C
Tuberculosis
Others

End User:

Hospitals
Diagnostic Laboratories
Clinics
Academic and Research Institutes
Others

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Product Code: PMRREP11413

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Production Adoption Analysis
4.2. Regulatory Scenario
4.3. Reimbursement Landscape
4.4. Supply Chain Analysis
4.5. PESTEL Analysis
4.6. Porter's Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Parent Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Development of Novel Products
- 5.2.2. Regulatory Imposition
- 5.2.3. Increasing Demand for Rapid Diagnostic Kits
- 5.2.4. Increasing Production Launches
- 5.2.5. Growing Government Investment
- 5.2.6. Strategic Mergers and Acquisitions Among Local
- 5.2.7. High Demand for PoC Testing
- 5.2.8. Rising Awareness about Early Testing
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Product
- 6.1.2. By Test Type
- 6.1.3. By Application
- 6.1.4. By End User
- 6.1.5. By Region
6.2. 2024 Market Scenario

7. Global Infectious Disease Diagnostic Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Product

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis, by Product, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Product, 2024-2033
8.4. Instrument
- 8.4.1. Biochips
- 8.4.2. Microfluidics Based POCT
- 8.4.3. DNA Microarrays
- 8.4.4. Mass Spectrometry
- 8.4.5. Real-time Polymerase Chain Reaction (qPCR)
- 8.4.6. Fluorescence in situ Hybridization (FISH)
- 8.4.7. Sequencing
- 8.4.8. Capillary Electrophoresis
- 8.4.9. Next Generation Sequencing
8.5. Kits and reagents
- 8.5.1. Kits
- 8.5.2. Primary antibodies
- 8.5.3. Secondary antibodies
- 8.5.4. Substrates
- 8.5.5. Buffers
8.6. consumables
8.7. Market Attractiveness Analysis, by Product

9. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Test Type

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Test Type, 2024-2033
- 9.3.1. Screening Test
- 9.3.2. Diagnostic Test
9.4. Market Attractiveness Analysis, by Test Type

10. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Application

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Application, 2024-2033
- 10.3.1. Hospital- Acquired Infections
- 10.3.2. Sexually Transmitted Disease (STD)
- 10.3.3. Sepsis
- 10.3.4. Meningitis
- 10.3.5. Respiratory Infections
- 10.3.6. HPV
- 10.3.7. Gastrointestinal Tract Infections
- 10.3.8. Infection in Transplant Patients
- 10.3.9. Hepatitis B and C
- 10.3.10. Tuberculosis
- 10.3.11. Others
10.4. Market Attractiveness Analysis, by Application

11. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By End User

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by End User, 2024-2033
- 11.3.1. Hospitals
- 11.3.2. Diagnostic Laboratories
- 11.3.3. Clinics
- 11.3.4. Academic and Research Institutes
- 11.3.5. Others

Market Attractiveness Analysis, by End User

12. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Region

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis, by Region

13. North America Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. U.S.
  - 13.3.1.2. Canada
- 13.3.2. By Product
- 13.3.3. By Test Type
- 13.3.4. By Application
- 13.3.5. By End User
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Product
- 13.4.3. By Test Type
- 13.4.4. By Application
- 13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. U.S. Infectious Disease Diagnostic Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 13.8.1.2.1. By Product
    - 13.8.1.2.2. By Test Type
    - 13.8.1.2.3. By Application
    - 13.8.1.2.4. By End User
- 13.8.2. Canada Infectious Disease Diagnostic Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 13.8.2.2.1. By Product
    - 13.8.2.2.2. By Test Type
    - 13.8.2.2.3. By Application
    - 13.8.2.2.4. By End User

14. Latin America Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. Mexico
  - 14.3.1.2. Brazil
  - 14.3.1.3. Argentina
  - 14.3.1.4. Rest of Latin America
- 14.3.2. By Product
- 14.3.3. By Test Type
- 14.3.4. By Application
- 14.3.5. By End User
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Product
- 14.4.3. By Test Type
- 14.4.4. By Application
- 14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. Mexico Infectious Disease Diagnostic Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.1.2.1. By Product
    - 14.8.1.2.2. By Test Type
    - 14.8.1.2.3. By Application
    - 14.8.1.2.4. By End User
- 14.8.2. Brazil Infectious Disease Diagnostic Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.2.2.1. By Product
    - 14.8.2.2.2. By Test Type
    - 14.8.2.2.3. By Application
    - 14.8.2.2.4. By End User
- 14.8.3. Argentina Infectious Disease Diagnostic Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.3.2.1. By Product
    - 14.8.3.2.2. By Test Type
    - 14.8.3.2.3. By Application
    - 14.8.3.2.4. By End User

15. Europe Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. Germany
  - 15.3.1.2. Italy
  - 15.3.1.3. France
  - 15.3.1.4. U.K.
  - 15.3.1.5. Spain
  - 15.3.1.6. BENELUX
  - 15.3.1.7. Russia
  - 15.3.1.8. Rest of Europe
- 15.3.2. By Product
- 15.3.3. By Test Type
- 15.3.4. By Application
- 15.3.5. By End User
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Product
- 15.4.3. By Test Type
- 15.4.4. By Application
- 15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Infectious Disease Diagnostic Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.1.2.1. By Product
    - 15.8.1.2.2. By Test Type
    - 15.8.1.2.3. By Application
    - 15.8.1.2.4. By End User
- 15.8.2. Italy Infectious Disease Diagnostic Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.2.2.1. By Product
    - 15.8.2.2.2. By Test Type
    - 15.8.2.2.3. By Application
    - 15.8.2.2.4. By End User
- 15.8.3. France Infectious Disease Diagnostic Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.3.2.1. By Product
    - 15.8.3.2.2. By Test Type
    - 15.8.3.2.3. By Application
    - 15.8.3.2.4. By End User
- 15.8.4. U.K. Infectious Disease Diagnostic Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.4.2.1. By Product
    - 15.8.4.2.2. By Test Type
    - 15.8.4.2.3. By Application
    - 15.8.4.2.4. By End User
- 15.8.5. Spain Infectious Disease Diagnostic Market Analysis
  - 15.8.5.1. Introduction
  - 15.8.5.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.5.2.1. By Product
    - 15.8.5.2.2. By Test Type
    - 15.8.5.2.3. By Application
    - 15.8.5.2.4. By End User
- 15.8.6. BENELUX Infectious Disease Diagnostic Market Analysis
  - 15.8.6.1. Introduction
  - 15.8.6.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.6.2.1. By Product
    - 15.8.6.2.2. By Test Type
    - 15.8.6.2.3. By Application
    - 15.8.6.2.4. By End User
- 15.8.7. Russia Infectious Disease Diagnostic Market Analysis
  - 15.8.7.1. Introduction
  - 15.8.7.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.7.2.1. By Product
    - 15.8.7.2.2. By Test Type
    - 15.8.7.2.3. By Application
    - 15.8.7.2.4. By End User

16. East Asia Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market End User (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. China
  - 16.3.1.2. Japan
  - 16.3.1.3. South Korea
- 16.3.2. By Product
- 16.3.3. By Test Type
- 16.3.4. By Application
- 16.3.5. By End User
16.4. Market Attractiveness Analysis
- 16.4.1. By Product
- 16.4.2. By Test Type
- 16.4.3. By Application
- 16.4.4. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. China Infectious Disease Diagnostic Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.1.2.1. By Product
    - 16.8.1.2.2. By Test Type
    - 16.8.1.2.3. By Application
    - 16.8.1.2.4. By End User
- 16.8.2. Japan Infectious Disease Diagnostic Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.2.2.1. By Product
    - 16.8.2.2.2. By Test Type
    - 16.8.2.2.3. By Application
    - 16.8.2.2.4. By End User
- 16.8.3. South Korea Infectious Disease Diagnostic Market Analysis
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.3.2.1. By Product
    - 16.8.3.2.2. By Test Type
    - 16.8.3.2.3. By Application
    - 16.8.3.2.4. By End User

17. South Asia Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. India
  - 17.3.1.2. Indonesia
  - 17.3.1.3. Malaysia
  - 17.3.1.4. Thailand
  - 17.3.1.5. Rest of South Asia
- 17.3.2. By Product
- 17.3.3. By Test Type
- 17.3.4. By Application
- 17.3.5. By End User
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Product
- 17.4.3. By Test Type
- 17.4.4. By Application
- 17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. India Infectious Disease Diagnostic Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.1.2.1. By Product
    - 17.8.1.2.2. By Test Type
    - 17.8.1.2.3. By Application
    - 17.8.1.2.4. By End User
- 17.8.2. Indonesia Infectious Disease Diagnostic Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.2.2.1. By Product
    - 17.8.2.2.2. By Test Type
    - 17.8.2.2.3. By Application
    - 17.8.2.2.4. By End User
- 17.8.3. Malaysia Infectious Disease Diagnostic Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.3.2.1. By Product
    - 17.8.3.2.2. By Test Type
    - 17.8.3.2.3. By Application
    - 17.8.3.2.4. By End User
- 17.8.4. Thailand Infectious Disease Diagnostic Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.4.2.1. By Product
    - 17.8.4.2.2. By Test Type
    - 17.8.4.2.3. By Application
    - 17.8.4.2.4. By End User

18. Oceania Infectious Disease Diagnostic Market 2019-2023 and Forecast 2024-2033

18.1. Introduction
18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 18.3.1. By Country
  - 18.3.1.1. Australia
  - 18.3.1.2. New Zealand
- 18.3.2. By Product
- 18.3.3. By Test Type
- 18.3.4. By Application
- 18.3.5. By End User
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Product
- 18.4.3. By Test Type
- 18.4.4. By Application
- 18.4.5. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
- 18.8.1. Australia Infectious Disease Diagnostic Market Analysis
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.1.2.1. By Product
    - 18.8.1.2.2. By Test Type
    - 18.8.1.2.3. By Application
    - 18.8.1.2.4. By End User
- 18.8.2. New Zealand Infectious Disease Diagnostic Market Analysis
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.2.2.1. By Product
    - 18.8.2.2.2. By Test Type
    - 18.8.2.2.3. By Application
    - 18.8.2.2.4. By End User

19. Middle East and Africa (MEA) Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

19.1. Introduction
19.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 19.3.1. By Country
  - 19.3.1.1. GCC Countries
  - 19.3.1.2. Turkiye
  - 19.3.1.3. South Africa
  - 19.3.1.4. North Africa
  - 19.3.1.5. Rest of Middle East and Africa
- 19.3.2. By Product
- 19.3.3. By Test Type
- 19.3.4. By Application
- 19.3.5. By End User
19.4. Market Attractiveness Analysis
- 19.4.1. By Product
- 19.4.2. By Test Type
- 19.4.3. By Application
- 19.4.4. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
- 19.8.1. GCC Countries Infectious Disease Diagnostic Market Analysis
  - 19.8.1.1. Introduction
  - 19.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.1.2.1. By Product
    - 19.8.1.2.2. By Test Type
    - 19.8.1.2.3. By Application
    - 19.8.1.2.4. By End User
- 19.8.2. Turkiye Infectious Disease Diagnostic Market Analysis
  - 19.8.2.1. Introduction
  - 19.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.2.2.1. By Product
    - 19.8.2.2.2. By Test Type
    - 19.8.2.2.3. By Application
    - 19.8.2.2.4. By End User
- 19.8.3. South Africa Infectious Disease Diagnostic Market Analysis
  - 19.8.3.1. Introduction
  - 19.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.3.2.1. By Product
    - 19.8.3.2.2. By Test Type
    - 19.8.3.2.3. By Application
    - 19.8.3.2.4. By End User
- 19.8.4. North Africa Infectious Disease Diagnostic Market Analysis
  - 19.8.4.1. Introduction
  - 19.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.4.2.1. By Product
    - 19.8.4.2.2. By Test Type
    - 19.8.4.2.3. By Application
    - 19.8.4.2.4. By End User

20. Market Structure Analysis

20.1. Market Analysis, by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis

21. Competition Analysis

21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
- 21.3.1. Affymetrix, Inc.
  - 21.3.1.1. Overview
  - 21.3.1.2. Product Portfolio
  - 21.3.1.3. Sales Footprint
  - 21.3.1.4. Key Financials
  - 21.3.1.5. SWOT Analysis
  - 21.3.1.6. Strategy Overview
    - 21.3.1.6.1. Marketing Strategy
    - 21.3.1.6.2. Product Strategy
    - 21.3.1.6.3. Channel Strategy
- 21.3.2. Ambion, Inc.
  - 21.3.2.1. Overview
  - 21.3.2.2. Product Portfolio
  - 21.3.2.3. Sales Footprint
  - 21.3.2.4. Key Financials
  - 21.3.2.5. SWOT Analysis
  - 21.3.2.6. Strategy Overview
    - 21.3.2.6.1. Marketing Strategy
    - 21.3.2.6.2. Product Strategy
    - 21.3.2.6.3. Channel Strategy
- 21.3.3. Applera Corporation
  - 21.3.3.1. Overview
  - 21.3.3.2. Product Portfolio
  - 21.3.3.3. Sales Footprint
  - 21.3.3.4. Key Financials
  - 21.3.3.5. SWOT Analysis
  - 21.3.3.6. Strategy Overview
    - 21.3.3.6.1. Marketing Strategy
    - 21.3.3.6.2. Product Strategy
    - 21.3.3.6.3. Channel Strategy
- 21.3.4. Cenetron Diagnostics
  - 21.3.4.1. Overview
  - 21.3.4.2. Product Portfolio
  - 21.3.4.3. Sales Footprint
  - 21.3.4.4. Key Financials
  - 21.3.4.5. SWOT Analysis
  - 21.3.4.6. Strategy Overview
    - 21.3.4.6.1. Marketing Strategy
    - 21.3.4.6.2. Product Strategy
    - 21.3.4.6.3. Channel Strategy
- 21.3.5. Cepheid, Inc.
  - 21.3.5.1. Overview
  - 21.3.5.2. Product Portfolio
  - 21.3.5.3. Sales Footprint
  - 21.3.5.4. Key Financials
  - 21.3.5.5. SWOT Analysis
  - 21.3.5.6. Strategy Overview
    - 21.3.5.6.1. Marketing Strategy
    - 21.3.5.6.2. Product Strategy
    - 21.3.5.6.3. Channel Strategy
- 21.3.6. Chiron Corporation
  - 21.3.6.1. Overview
  - 21.3.6.2. Product Portfolio
  - 21.3.6.3. Sales Footprint
  - 21.3.6.4. Key Financials
  - 21.3.6.5. SWOT Analysis
  - 21.3.6.6. Strategy Overview
    - 21.3.6.6.1. Marketing Strategy
    - 21.3.6.6.2. Product Strategy
    - 21.3.6.6.3. Channel Strategy
- 21.3.7. Dharmacon, Inc.
  - 21.3.7.1. Overview
  - 21.3.7.2. Product Portfolio
  - 21.3.7.3. Sales Footprint
  - 21.3.7.4. Key Financials
  - 21.3.7.5. SWOT Analysis
  - 21.3.7.6. Strategy Overview
    - 21.3.7.6.1. Marketing Strategy
    - 21.3.7.6.2. Product Strategy
    - 21.3.7.6.3. Channel Strategy
- 21.3.8. Digene Corporation
  - 21.3.8.1. Overview
  - 21.3.8.2. Product Portfolio
  - 21.3.8.3. Sales Footprint
  - 21.3.8.4. Key Financials
  - 21.3.8.5. SWOT Analysis
  - 21.3.8.6. Strategy Overview
    - 21.3.8.6.1. Marketing Strategy
    - 21.3.8.6.2. Product Strategy
    - 21.3.8.6.3. Channel Strategy
- 21.3.9. Gen-Probe Incorporated
  - 21.3.9.1. Overview
  - 21.3.9.2. Product Portfolio
  - 21.3.9.3. Sales Footprint
  - 21.3.9.4. Key Financials
  - 21.3.9.5. SWOT Analysis
  - 21.3.9.6. Strategy Overview
    - 21.3.9.6.1. Marketing Strategy
    - 21.3.9.6.2. Product Strategy
    - 21.3.9.6.3. Channel Strategy
- 21.3.10. Innogenetics NV
  - 21.3.10.1. Overview
  - 21.3.10.2. Product Portfolio
  - 21.3.10.3. Sales Footprint
  - 21.3.10.4. Key Financials
  - 21.3.10.5. SWOT Analysis
  - 21.3.10.6. Strategy Overview
    - 21.3.10.6.1. Marketing Strategy
    - 21.3.10.6.2. Product Strategy
    - 21.3.10.6.3. Channel Strategy
- 21.3.11. Nanogen, Inc.
  - 21.3.11.1. Overview
  - 21.3.11.2. Product Portfolio
  - 21.3.11.3. Sales Footprint
  - 21.3.11.4. Key Financials
  - 21.3.11.5. SWOT Analysis
  - 21.3.11.6. Strategy Overview
    - 21.3.11.6.1. Marketing Strategy
    - 21.3.11.6.2. Product Strategy
    - 21.3.11.6.3. Channel Strategy
- 21.3.12. F. Hoffmann-La Roche Ltd
  - 21.3.12.1. Overview
  - 21.3.12.2. Product Portfolio
  - 21.3.12.3. Sales Footprint
  - 21.3.12.4. Key Financials
  - 21.3.12.5. SWOT Analysis
  - 21.3.12.6. Strategy Overview
    - 21.3.12.6.1. Marketing Strategy
    - 21.3.12.6.2. Product Strategy
    - 21.3.12.6.3. Channel Strategy
- 21.3.13. Becton, Dickinson and Company
  - 21.3.13.1. Overview
  - 21.3.13.2. Product Portfolio
  - 21.3.13.3. Sales Footprint
  - 21.3.13.4. Key Financials
  - 21.3.13.5. SWOT Analysis
  - 21.3.13.6. Strategy Overview
    - 21.3.13.6.1. Marketing Strategy
    - 21.3.13.6.2. Product Strategy
    - 21.3.13.6.3. Channel Strategy
- 21.3.14. bioMerieux SA
  - 21.3.14.1. Overview
  - 21.3.14.2. Product Portfolio
  - 21.3.14.3. Sales Footprint
  - 21.3.14.4. Key Financials
  - 21.3.14.5. SWOT Analysis
  - 21.3.14.6. Strategy Overview
    - 21.3.14.6.1. Marketing Strategy
    - 21.3.14.6.2. Product Strategy
    - 21.3.14.6.3. Channel Strategy
- 21.3.15. Hologic, Inc.
  - 21.3.15.1. Overview
  - 21.3.15.2. Product Portfolio
  - 21.3.15.3. Sales Footprint
  - 21.3.15.4. Key Financials
  - 21.3.15.5. SWOT Analysis
  - 21.3.15.6. Strategy Overview
    - 21.3.15.6.1. Marketing Strategy
    - 21.3.15.6.2. Product Strategy
    - 21.3.15.6.3. Channel Strategy
- 21.3.16. QIAGEN
  - 21.3.16.1. Overview
  - 21.3.16.2. Product Portfolio
  - 21.3.16.3. Sales Footprint
  - 21.3.16.4. Key Financials
  - 21.3.16.5. SWOT Analysis
  - 21.3.16.6. Strategy Overview
    - 21.3.16.6.1. Marketing Strategy
    - 21.3.16.6.2. Product Strategy
    - 21.3.16.6.3. Channel Strategy
- 21.3.17. Myriad Genetics, Inc.
  - 21.3.17.1. Overview
  - 21.3.17.2. Product Portfolio
  - 21.3.17.3. Sales Footprint
  - 21.3.17.4. Key Financials
  - 21.3.17.5. SWOT Analysis
  - 21.3.17.6. Strategy Overview
    - 21.3.17.6.1. Marketing Strategy
    - 21.3.17.6.2. Product Strategy
    - 21.3.17.6.3. Channel Strategy
- 21.3.18. Thermo Fisher Scientific
  - 21.3.18.1. Overview
  - 21.3.18.2. Product Portfolio
  - 21.3.18.3. Sales Footprint
  - 21.3.18.4. Key Financials
  - 21.3.18.5. SWOT Analysis
  - 21.3.18.6. Strategy Overview
    - 21.3.18.6.1. Marketing Strategy
    - 21.3.18.6.2. Product Strategy
    - 21.3.18.6.3. Channel Strategy
- 21.3.19. Meridian Bioscience, Inc.
  - 21.3.19.1. Overview
  - 21.3.19.2. Product Portfolio
  - 21.3.19.3. Sales Footprint
  - 21.3.19.4. Key Financials
  - 21.3.19.5. SWOT Analysis
  - 21.3.19.6. Strategy Overview
    - 21.3.19.6.1. Marketing Strategy
    - 21.3.19.6.2. Product Strategy
    - 21.3.19.6.3. Channel Strategy